Deferiprone is under clinical development by Chiesi Farmaceutici and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Deferiprone’s likelihood of approval (LoA) and phase transition for Parkinson’s Disease took place on 12 Dec 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Deferiprone Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Deferiprone (Ferriprox) is an iron chelating agent. It is formulated as solution, tablets and film coated tablets for oral route of administration. Ferriprox is indicated for the treatment of transfusional iron overload in adult and pediatric patients 3 years of age and older with thalassemia syndromes and sickle cell disease or other anemias. Ferriprox is indicated for the treatment of patients with transfusional iron overload due to sickle cell disease or other anemias.
It is under development for the treatment of pantothenate kinase-associated neurodegeneration, Parkinson’s disease, amyotrophic lateral sclerosis and HIV. The drug candidate is administered orally and through intravenous route. The drug candidate was also under development for the treatment of Friedreich Ataxia.
Chiesi Farmaceutici overview
Chiesi Farmaceutici (Chiesi) researches, develops, produces and commercializes novel medicines with a focus on respiratory, neonatology, rare disease and special care therapeutic areas. The company provides products for the treatment of chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, ankylosing spondylitis, hypertension, percutaneous coronary intervention, apnoea of prematurity, respiratory distress syndrome, lipoprotein lipase deficiency (LPLD), limbal stem cell deficiency (LSCD) and inflammatory bowel diseases, among others. The company operates production sites in Parma, Italy; Blois, France; and Santana De Parnaiba, Brazil; and conducts research and development activities at its R&D center in Parma and at laboratories in Paris (France), Chippenham (the UK), Cary (the US) and Lidingo (Sweden). Chiesi is headquartered in Parma, Emilia-Romagna, Italy.
Quick View Deferiprone LOA Data
|Highest Development Stage|